With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

Achieving and maintaining a healthy weight is beneficial for a number of reasons. A healthy weight lowers a person's chance ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

My weight concerns mainly injure my considerable vanity, and I’m not about to outsource my self-esteem issue to Big Pharma if ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Tirzepatide (15 mg once weekly), a dual agonist targeting GLP-1 and GIP receptors, produced weight loss of up to 17.8% after 72 weeks, and semaglutide (2.4 mg once weekly) produced weight loss of ...

On the one hand, its impressive business performance can make investors ponder potential life-changing investment returns. Conversely, feeling confident in Hims & Hers Health can sometimes be ...

Sun Pharmaceutical Industries Ltd. has divulged incretin analogues acting as dual agonists of gastric inhibitory polypeptide (GIPR) receptor/GLP-1 or GLP-1/glucagon receptor (GCGR) or triple agonists ...